Shares of JOYY Inc (NASDAQ:JOYY) rose sharply in pre-market trading after the company reported financial results for the second quarter.

JOYY reported quarterly earnings of $1.24 per share which missed the analyst consensus estimate of $1.28 per share. The company reported quarterly sales of $590.754 million which beat the analyst consensus estimate of $574.118 million.

JOYY said it sees third-quarter sales of $602.000 million-$622.000 million, versus market estimates of $591.756 million.

JOYY shares jumped 3.6% to $77.70 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers

• Reading International Inc (NASDAQ:RDIB) gained 98.4% to $18.85 in pre-market trading after jumping around 9% on Tuesday.
• YY Group Holding Ltd (NASDAQ:YYGH) rose 74% to $2.00 in pre-market trading after the company announced the cancellation of a $5.94 million second financing tranche and all outstanding warrants.
• CID HoldCo Inc (NASDAQ:DAIC) rose 44.9% to $5.62 in pre-market trading after surging 124% on Tuesday.
• Lucas GC Ltd (NASDAQ:LGCL) rose 32.1% to $0.058 in pre-market trading after dipping over 6% on Tuesday.
• Founder Group Ltd (NASDAQ:FGL) gained 29.2% to $0.27 in pre-market trading. On Tuesday, Founder Group announced that it has completed the acquisition of a 19.90% equity interest in Nichcom Go Sdn. Bhd.
• Trugolf Holdings Inc (NASDAQ:TRUG) gained 27.8% to $0.75 in pre-market trading after declining 10% on Tuesday. TruGolf recently announced it will acquire tokenization technology company Polymath Research For ~19.9% Of TRUG Class A Shares Outstanding.
• Expion360 Inc (NASDAQ:XPON) rose 25% to $6.59 in pre-market trading after dropping 15% on Tuesday. Expion360 recently announced a $3.425 million acquisition of Eastern Louisiana Oil ans Gas Exploration Prospect.
• Biohaven Ltd (NYSE:BHVN) rose 9.6% to $15.76 in pre-market trading. Biohaven and SK Biopharmaceuticals entered into a strategic global licensing agreement for novel Kv7 ion channel platform and opakalim, lead candidate for epilepsy.
• Anbio Biotechnology (NASDAQ:NNNN) shares gained 7.4% to $8.41 in pre-market trading.

Losers

• Greenland Mines Ltd (NASDAQ:GRML) tumbled 29% to $6.90 in pre-market trading after announcing a proposed public offering.
• Netcapital Inc (NASDAQ:NCPL) fell 24.8% to $0.44 in pre-market trading after jumping over 126% on Tuesday.
• Xiao-I Corp (NASDAQ:AIXI) fell 16.8% to $1.09 in pre-market trading after jumping 186% on Tuesday. Xiao-I recently announced it will change its ADS ratio from 1‑to‑60 to 1‑to‑420 ordinary shares and disclosed it received a non‑compliance notice from Nasdaq.
• Akanda Corp (NASDAQ:AKAN) declined 15% to $4.21 in pre-market trading after jumping 34% on Tuesday.
• Advasa Holdings (NASDAQ:ADBT) fell 14.1% to $5.38 in pre-market trading after dipping around 48% on Tuesday. Advasa Holdings, on Tuesday, completed a direct listing on Nasdaq under the ticker symbol “ADBT”.
• Biodexa Pharmaceuticals PLC-ADR (NASDAQ:BDRX) fell 13.6% to $1.02 in pre-market trading.
• 707 Cayman Holdings Ltd (NASDAQ:JEM) fell 12.4% to $5.95 in pre-market trading. 707 Cayman Holdings shares jumped 78% on Tuesday after the company announced signing of a term sheet to acquire Crucial Innovation, supported by $10.25 million financing led by GeoNova Holdings.
• Spyre Therapeutics Inc (NASDAQ:SYRE) fell 12.3% to $94.16 in pre-market trading after the company announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. The results did not meet the company’s internal bar to prioritize advancement of SPY072 in RA.
• Intuit Inc (NASDAQ:INTU) fell 11.7% to $315.50 in pre-market trading after the company reported upbeat fourth-quarter financial results but issued FY27 guidance below estimates.
• Zoom Communications Inc (NASDAQ:ZM) fell 5.8% to $95.10 in pre-market trading as the company reported better-than-expected financial results for the second quarter but issued soft guidance for the third quarter.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.